Aclaris Therapeutics ACRS Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Revenue by Product | |||||
| Dermatology Therapeutics | $5.95M-63.2% | $16.18M-42.7% | $28.21M+11.3% | $25.36M+2,620% | |
| Research And Development Project Spend by Product | |||||
| Drug Candidate Ati052 | $7.07M+273% | $1.9M— | —— | —— | |
| Drug Candidate Ati2138 | $4.92M+16.9% | $4.21M-65.3% | $12.14M— | —— | |
| Drug Candidate Bosakitug | $13.85M+4,530% | $299K— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Aclaris Therapeutics break its business down?
- Aclaris Therapeutics (ACRS) reports revenue by product across 2 parts — Contract Research and Dermatology Therapeutics. Each is extracted from the segment footnotes and tracked over time.
- Where does Aclaris Therapeutics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Aclaris Therapeutics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
